One Day Advisor

Based on full-year 2025 results and Q2 2026 earnings reported through early August 2026, Johnson & Johnson ($94.2 billion FY2025 revenue; 2026 guidance just raised to ~$101.1 billion) remains the world's largest pharmaceutical/healthcare company by revenue, followed by China's Sinopharm Group (~$80 billion, primarily a distributor), Roche (~$70 billion), Eli Lilly ($65.2 billion FY2025, +45%; Q2 2026 revenue jumped 47.7% YoY to $22.97 billion, guidance now raised to $85–87 billion), Merck & Co. ($65.0 billion; Q2 2026 guidance raised to $66.3–67.3 billion), Pfizer ($62.6 billion; guidance raised to $60.5–62.5 billion), AbbVie ($61.2 billion; Q2 2026 revenue up 10.2% to $16.99 billion, guidance raised to ~$67.6 billion), AstraZeneca ($58.7 billion), Novartis ($54.5 billion) and Bristol Myers Squibb ($48.2 billion) rounding out the top 10. By market capitalization, Eli Lilly is far ahead of every rival at roughly $1.12 trillion as of early August 2026 — more than Johnson ...

As AI continues to reshape creator workflows, research, and on‑device inference, demand for powerful GPUs remains at an all‑time high. In 2026, AI‑focused GPUs — especially those with large VRAM and optimized AI cores — are consistently topping Amazon sales charts, combining performance for local AI workloads with broader ecosystem support. AMD's Radeon RX 9000 series, built on the RDNA 4 architecture, is a strong contender with significant improvements in AI performance. These GPUs feature advanced AI accelerators, support major machine learning frameworks, and have competitive memory configurations (up to 32GB GDDR6). While AMD's Radeon RX 9000 series offers excellent AI capabilities and improved efficiency, NVIDIA's GPUs still generally lead due to their superior ray tracing, AI upscaling technologies (such as DLSS 4), and broader industry adoption for AI workloads. Therefore, NVIDIA's RTX 50 series currently dominates AI performance and market pr...